Outcomes with SCT in large historical patient series
Reference . | N . | TRM (%) . | RR/CR* (%) . | Organ responses (%) . | Median survival, y . | MEL 200/reduced dose (%) . |
---|---|---|---|---|---|---|
17 | 312 | 16 | NA/27 | 26 | 4.6 | 56/44 |
97 | 270 | 11 | 71/33 | NA | NR | 67/33 |
98 | 92 | 23 | 37/20 | NA | 5.3 | 69/31 |
99 | 107 | 27 | 32/16 | 26 | 3.9 | 46/54 |
Reference . | N . | TRM (%) . | RR/CR* (%) . | Organ responses (%) . | Median survival, y . | MEL 200/reduced dose (%) . |
---|---|---|---|---|---|---|
17 | 312 | 16 | NA/27 | 26 | 4.6 | 56/44 |
97 | 270 | 11 | 71/33 | NA | NR | 67/33 |
98 | 92 | 23 | 37/20 | NA | 5.3 | 69/31 |
99 | 107 | 27 | 32/16 | 26 | 3.9 | 46/54 |
N indicates number of patients; TRM, treatment-related mortality; NA, not available; RR, overall response rate (partial and complete); NR, not reached; MEL 200, melphalan at 200 mg/m2; reduced dose, MEL 140 or 100 mg/m2.
CR indicates complete hematologic response. It is important to note that the definition of CR has undergone revision since these reports with inclusion of free light chain measurements. Strict CR in AL can now be defined as serum and urine immunofixation with no evidence of the prior monoclonal protein, normalization of pathologic FLC, and κ-to-λ ratio, and marrow aspirate with less than 5% plasma cells without isotype restriction.21